Breast Cancer
Conditions
Interventions
Group 1:neoadjuvant docetaxel,lobaplatin and trastuzumab
Group 2:neoadjuvant docetaxel,carboplatin and trastuzumab
Sponsors
First Affiliated Hospital of Army Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1) Aged 18 to 65 years old; 2) Stage I to III breast cancer before surgery. Diagnosed by pathological examination with hollow needle biopsy before therapy started and resectable. IHC method examination showed: ER(-), PR(-), HER-2/neu(+); 3) The size of the cancer is measurable; 4) With no distant metastasis according to abdominal ultrasound and breast X-ray and whole body bone scan and fine needle aspiration to local lymph node enlargement. With no other malignancy; 5) Capable to follow the scheme; 6) ECOG score as 0 or 1; 7) Willing to join in the study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1) Being pregnant or breasting-feeding; 2) With serve complication of heart, liver, kidney or endocrine system and with expected survival period less than 2 year; 3) Allergic to the drugs involved in the study; 4) Karnofsky score less than 60; 5) Unable to accept investigation on time; 6) Not suitable for the trial because of other reasons according to the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pCR (pathologic complete response);overall survival;disease-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Conmon terminology criteria adverseevents;CR (complete response);PR (partial response);SD (stable disease);PR (progressive disease); | — |
Countries
China
Contacts
Public ContactYi Zhang
First Affiliated Hospital of Army Medical University
Outcome results
None listed